

the receiver operating characteristic curves (ROC), sensitivity, and specificity measures with Bonferroni adjustment for multiple testing applied were performed to compare the models' performance. **Results:** Among 15964 identified patients, a MALE occurred in 26.02% of patients, and death occurred in 18.82% of patients. The most effective predictive model for MALE, as determined by the AUC, was the gradient boosted decision tree (AUC= 0.7539) followed by the LASSO regularized GLM (AUC= 0.749). The most effective predictive model for mortality was the LASSO regularized GLM (AUC=0.7930) followed by the GLM model (AUC=0.7922). The GLM, LASSO regularized GLM model, and gradient boosted decision tree produced similar ROC. **Conclusions:** All models showed acceptable discrimination, with an AUC greater than 0.7, when predicting MALE and mortality among patients receiving treatment for lower extremity peripheral artery disease. The machine learning techniques outperformed traditional regression-based techniques and can be leveraged to generate robust predictive models within the clinical space of lower extremity PAD.

## Comparative Effectiveness Studies

### CE1

#### A MODELED HEALTH OUTCOMES EVALUATION OF DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINA

Ming J,<sup>1</sup> Liu Y,<sup>1</sup> Lu W,<sup>1</sup> Wu Y,<sup>1</sup> Li W,<sup>1</sup> Han R,<sup>2</sup> Hu S<sup>3</sup>

<sup>1</sup>IQVIA, Shanghai, China, <sup>2</sup>Bayer Healthcare Company Ltd., Beijing, China, <sup>3</sup>School of Public Health, Fudan University, Shanghai, China

**Objectives:** Novel antiandrogens have demonstrated clinical benefit for patients with non-metastatic castration resistant prostate cancer (nmCRPC). We modeled the incremental life-years and QALYs of darolutamide+ADT compared to apalutamide+ADT and enzalutamide+ADT, for high-risk nmCRPC, in a Chinese setting. **Methods:** A partitioned survival model with three health states (nmCRPC, metastatic CRPC and death) was devised. Data from the ARAMIS, PROSPER and SPARTAN trials were used, in the absence of head-to-head studies. Hazard ratios (HRs) characterizing overall survival (OS) were derived from formal indirect treatment comparisons of the OS HRs between the three trials; the point estimates of the OS HRs characterizing the indirect comparison of darolutamide+ADT vs apalutamide+ADT and enzalutamide+ADT were 0.88 and 0.95, respectively. Parametric survival functions were selected for extrapolation based on the goodness of fit. The baseline characteristics, treatment patterns and utilities for this modeled Chinese cohort were validated with 12 urologists from 11 hospitals. A discount rate of 5% was applied. Univariate and probabilistic sensitivity analyses were performed. **Results:** With a 20-year modeling horizon, darolutamide+ADT yielded more life years (5.98LYs) and QALYs (4.61QALYs) than both apalutamide+ADT (5.64LYs, 4.43QALYs) and enzalutamide+ADT (5.82LYs, 4.55QALYs). The incremental QALY gains with darolutamide+ADT vs. apalutamide+ADT (+0.18QALYs) and vs. enzalutamide+ADT (+0.06QALYs) were mainly driven by the improved life years during post-progression survival (+0.92LYs vs. apalutamide+ADT and +0.65LYs vs. enzalutamide+ADT). Results were sensitive to the HRs and utility inputs; however, the probabilities of darolutamide+ADT having incremental QALYs reached 70.4% and 56.8% when compared to apalutamide+ADT and enzalutamide+ADT, respectively. **Conclusions:** This modeled evaluation indicates that darolutamide+ADT is likely to be associated with incremental health outcomes over apalutamide+ADT and enzalutamide+ADT, for a high-risk nmCRPC Chinese cohort, over a 20-year time-frame.

### CE2

#### EFFECT OF DIFFERENT VARIANCE ESTIMATION METHODS WITH INVERSE PROBABILITY TREATMENT WEIGHTS (IPTW) ON COMPARATIVE EFFECTIVENESS MEASURE IN MULTIPLE SCLEROSIS

Earla J,<sup>1</sup> Hutton GJ,<sup>2</sup> Thornton JD,<sup>3</sup> Chen H,<sup>4</sup> Johnson ML,<sup>4</sup> Aparasu RR<sup>4</sup>

<sup>1</sup>Incyte Corporation, Chadds Ford, PA, USA, <sup>2</sup>Baylor College of Medicine Medical Center, McNair Campus, Houston, TX, USA, <sup>3</sup>University of Houston, The Prescription Drug Misuse Education and Research (PREMIER) Center, Houston, TX, USA, <sup>4</sup>University of Houston, Houston, TX, USA

**Objectives:** The Inverse Probability Treatment Weighting (IPTW) method provides marginal treatment effects that are more generalizable than other propensity score (PS) methods. The objective of this study was to compare the treatment effects from three different variance estimation methods with stabilized IPTWs on comparative effectiveness between oral fingolimod and injectable Disease Modifying Agents (DMA) users in Multiple Sclerosis (MS). **Methods:** This longitudinal retrospective study used adults (≥18 years) with MS diagnosis (ICD-9-CM:340) and a DMA prescription from the IBM MarketScan Commercial Claims and Encounters Database from 2010–2012. Patients were classified into fingolimod or injectable users based on their initial DMA prescription. The composite endpoint (time-to-relapse/DMA switch) was assessed during the one-year follow-up period after DMA initiation. The

stabilized IPTW-Cox Proportional Hazards regression model was used to evaluate the composite endpoint with three different variance estimators – (i)Naïve, (ii)Robust sandwich-type, and (iii)Bootstrapping(200 replications). Patients who died/were lost from follow-up due to the lack of insurance coverage were censored. **Results:** The new DMA user study cohort consisted of 1,700 MS patients who were initiated with oral(15.82%) or injectable(84.18%) DMAs during 2010-2011. The proportion of patients who had a composite endpoint in fingolimod and injectable DMA users was 16.72% and 27.16%, respectively. The stabilized IPTW-Cox model with naïve and bootstrapping variance estimators revealed that oral fingolimod users were superior to injectable DMAs in reducing the risk of composite endpoint (Naïve estimator: Adjusted Hazards Ratio [aHR]-0.67, 95%CI:0.51-0.87; Bootstrapped estimator: aHR-0.68, 95%CI:0.39-0.97). However, the findings were not significant in the IPTW-Cox model with robust sandwich estimator(aHR-0.67, 95%CI:0.43-1.03). **Conclusions:** The analyses revealed that the significance of treatment effect estimates could vary depending on the choice of variance estimation method. Hence, researchers should pay attention to the selection of variance estimation method with small samples in addition to handling of extreme weights while using IPTWs for time-to-event analyses.

### CE3

#### SYSTEMATIC REVIEW AND INDIRECT COMPARISON OF PD-(L)1 INHIBITORS IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS, NON-SMALL-CELL LUNG CANCER (NSQNSCLC)

Zhang L,<sup>1</sup> Qian Y,<sup>2</sup> Li J,<sup>2</sup> Cui C,<sup>2</sup> Chen L,<sup>2</sup> Qu S,<sup>3</sup> Lu S<sup>4</sup>

<sup>1</sup>Eli Lilly and Company, Shanghai, 31, China, <sup>2</sup>Eli Lilly and Company, Shanghai, China, <sup>3</sup>Real World Solutions, IQVIA, Shanghai, China, <sup>4</sup>Shanghai Chest Hospital, Shanghai, China

**Objectives:** To evaluate relative efficacy and safety of sintilimab compared with other PD-(L)1 inhibitors in combination with platinum-based doublet chemotherapy (PT-DC) for the first-line treatment of nsqNSCLC. **Methods:** A systematic literature search was conducted based on published studies in electronic databases up to December 2020. Eligible randomized controlled trials (RCT) that investigated untreated locally advanced or metastatic nsqNSCLC without activating EGFR mutations or ALK translocations patients were analyzed. Outcomes evaluated by adjusted indirect treatment comparison (ITC) using Bucher method mainly included progression-free survival (PFS), objective response rate (ORR), time to response (TTR) and safety profile. Taking the heterogeneity into account, random-effect model will be applied if the p-value of Chi-square test greater than 0.05. **Results:** Seven RCTs involving 3,559 patients were included. ITC results suggested that combined PT-DC with sintilimab had a comparable PFS compared with that of combined PT-DC with pembrolizumab (HR=1.00, 95%CI: 0.71 to 1.41), atezolizumab (HR=0.81, 95%CI: 0.59 to 1.10), tislelizumab (HR= 0.75, 95%CI: 0.48 to 1.16), camrelizumab (HR=0.80, 95%CI:0.54 to 1.20) and nivolumab (HR=0.72, 95%CI : 0.51 to 1.02). Little differences were found in ORR between combined PT-DC with sintilimab and combined PT-DC with pembrolizumab (OR=0.66, 95%CI: 0.37 to 1.20), atezolizumab (OR=1.23, 95%CI: 0.70 to 2.14), tislelizumab (OR=1.11, 95%CI: 0.58 to 2.11), camrelizumab (OR=1.05, 95%CI: 0.58 to 1.90) and nivolumab (OR=1.14, 95%CI: 0.64 to 2.00). Incidence of all grades or grades ≥3 adverse events (AE) were comparable between combined PT-DC with sintilimab and other PD-(L)1s. For AE leading to discontinuation, the incidence of sintilimab in combination with PT-DC is significantly lower than that of pembrolizumab in combination with PT-DC (OR=0.27, 95% CI: 0.11 to 0.67). **Conclusions:** Combined PT-DC with sintilimab and other PD-(L)1 inhibitors had comparable efficacy and safety profile for the first-line treatment of locally advanced or metastatic nsqNSCLC patients.

### CE4

#### EXPANDING EVIDENCE BASE VS INTRODUCING HETEROGENEITY IN NETWORKS FOR NETWORK META-ANALYSES: A SIMULATION STUDY

Luttenauer H,<sup>1</sup> Le Nouveau P,<sup>2</sup> Gauthier A<sup>3</sup>

<sup>1</sup>Amaris Consulting, London, UK, <sup>2</sup>Amaris Consulting, Levallois-Perret, ON, France, <sup>3</sup>Amaris Consulting, Barcelona, Spain

**Objectives:** Network meta-analyses (NMAs) are widely used to estimate the relative treatment effect between treatments that have not directly been compared in clinical trials. Challenges arise in precision medicines, where only small networks of evidence are available. This study aimed to explore the trade-off between increasing the evidence base by including additional studies and increasing the level of heterogeneity in the network considered. **Methods:** Data were simulated to reflect a small network including four treatments. Four scenarios were simulated with increasing number of studies per direct comparison. Each study was assumed to add an additional level of heterogeneity in the network, that was partly explained by an observable covariate. Scenario 1 represented a small network with a low level of heterogeneity while scenario 4 was a bigger network with a higher heterogeneity level. Standard NMAs were conducted and the mean relative difference (MRD) between the NMA estimates